Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Radiopharm Theranostics Limited ( (AU:RAD) ).
Radiopharm Theranostics has appointed Dr. Oliver Sartor to its Scientific Advisory Board. Dr. Sartor, a renowned medical oncologist specializing in prostate cancer and radiopharmaceutical therapies, brings extensive expertise that is expected to significantly enhance the company’s radiopharmaceutical pipeline and strengthen its position in the oncology sector.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited is a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need. The company is listed on ASX and NASDAQ and has a pipeline of distinct platform technologies spanning peptides, small molecules, and monoclonal antibodies for use in cancer diagnostics and therapeutics.
Average Trading Volume: 2,234,033
Technical Sentiment Signal: Sell
Current Market Cap: A$52.03M
See more insights into RAD stock on TipRanks’ Stock Analysis page.